ReviewMolecular biology reports2025
Diabetic retinopathy: a comprehensive review of pathophysiology and emerging treatments.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- From xanthine oxidase inhibition to inflammasome regulation: exploring the potential role of allopurinol in TXNIP-NLRP3 signaling and pyroptosis in diabetes.Inflammopharmacology · 2026Review
- Article
- SD-OCT vs FA in diabetic retinopathy: a sensitivity-specificity tradeoff in detecting intraretinal macroaneurysms.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Aldose reductase as a regulator of ocular pathology: Mechanisms and therapeutic potential.Histology and histopathology · 2026Review
- Article
- Review
- Integrative transcriptomic and machine learning analysis identifies key extracellular matrix-related genes in diabetic retinopathy.Scientific reports · 2026Article
- Microaneurysm segmentation under out-of-domain generalization: from diabetic retinopathy to leukemic retinopathy.International journal of retina and vitreous · 2026Article
- Editorial of Special Issue "Molecular Research and Recent Advances in Diabetic Retinopathy: Second Edition".Biomedicines · 2026Article
- Semi-supervised 3D diabetic macular edema segmentation in OCT volumes via independent dual-branch consistency learning.Biomedical optics express · 2026Article
- Association of theFrontiers in medicine · 2026Article
- Atypical p38 Kinase Signaling in Retinal Vascular Damage and Recovery.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Formulation of α-Linolenic Acid-Based Microemulsions for Age-Related Macular Degeneration: Physicochemical Tests and HET-CAM Assays for Anti-Angiogenic Activities.Medicina (Kaunas, Lithuania) · 2025Article
- METTL3-mediated mMolecular biology reports · 2025Review
- Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations.Diabetology & metabolic syndrome · 2025Article
- Resveratrol as a Novel Therapeutic Approach for Diabetic Retinopathy: Molecular Mechanisms, Clinical Potential, and Future Challenges.Molecules (Basel, Switzerland) · 2025Review
- An Investigation of 5-HalogenatedMedicines (Basel, Switzerland) · 2025Article
- Corneal Endothelial Changes After Phacoemulsification Using the Eight-Chop Technique in Diabetic Eyes.Journal of personalized medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetic retinopathy constitutes a major complication associated with diabetes mellitus, resulting in visual impairment and blindness on a global scale. The pathophysiology of DR is characterized by intricate interactions among metabolic, hemodynamic, and inflammatory pathways, which include the activation of the polyol pathway, the accumulation of advanced glycation end products, the overactivation of protein kinase C, dysregulation of the renin-angiotensin-aldosterone system, and retinal neurodegeneration. This review investigates the classification, complex pathophysiology, and therapeutic modalities for DR, encompassing conventional interventions such as anti-VEGF agents, aldose reductase inhibitors, angiotensin receptor blockers, laser photocoagulation, and vitrectomy. Innovative treatments, including advanced anti-VEGF agents, neuroprotective strategies, gene and stem cell therapies, and advancements in drug delivery systems, exhibit considerable transformative potential. Furthermore, integrating artificial intelligence for early detection and modulation of inflammatory pathways signifies cutting-edge progress in the field. By integrating contemporary knowledge and prospective avenues, this review underscores the significance of comprehending the multifaceted nature of DR and the advancements in its therapeutic approaches. The objective is to bridge the gaps between research findings and clinical application, thereby providing a comprehensive resource to enhance outcomes and quality of life for individuals impacted by DR.
Indexed as
Identifiers
40205024What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.